Zacks Investment Research Upgrades Adaptimmune Therapeutics PLC (ADAP) to Hold
According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “
Separately, Raymond James Financial Inc. started coverage on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 30th. They set an outperform rating and a $16.00 target price on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Adaptimmune Therapeutics PLC currently has an average rating of Buy and an average target price of $15.95.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at 5.90 on Monday. Adaptimmune Therapeutics PLC has a 52-week low of $5.53 and a 52-week high of $14.78. The stock has a 50 day moving average of $6.98 and a 200-day moving average of $8.38. The firm’s market cap is $417.63 million.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.16. Adaptimmune Therapeutics PLC had a negative net margin of 427.33% and a negative return on equity of 21.36%. On average, analysts expect that Adaptimmune Therapeutics PLC will post ($1.09) EPS for the current year.
Several institutional investors have recently bought and sold shares of ADAP. Renaissance Technologies LLC raised its position in Adaptimmune Therapeutics PLC by 286.3% in the first quarter. Renaissance Technologies LLC now owns 113,200 shares of the company’s stock valued at $920,000 after buying an additional 83,900 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Adaptimmune Therapeutics PLC by 35.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock valued at $9,350,000 after buying an additional 300,000 shares during the period. Springbok Capital Management LLC acquired a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $202,000. Opaleye Management Inc. acquired a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $1,425,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Adaptimmune Therapeutics PLC by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock valued at $888,000 after buying an additional 3,519 shares during the period. Institutional investors own 45.11% of the company’s stock.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.